Company profile for ARTHEx Biotech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. ARTHEx has developed its proprietary technology, the ENTRY ™ platform, that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevan...
ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. ARTHEx has developed its proprietary technology, the ENTRY ™ platform, that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Spain
Address
Address
C/ Catedrático Agustín Escardino 9 46980 Paterna, Valencia
Telephone
Telephone
+34 625 016 629
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/arthex-biotech-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-302412852.html

PR NEWSWIRE
27 Mar 2025

https://www.prnewswire.com/news-releases/arthex-biotech-announces-oral-presentation-on-atx-01-at-tides-europe-annual-meeting-2024-302300806.html

PR NEWSWIRE
11 Nov 2024

https://www.prnewswire.com/news-releases/arthex-biotech-announces-fda-rare-pediatric-designation-rpd-of-atx-01-for-the-treatment-of-myotonic-dystrophy-type-1-dm1-302298244.html

PR NEWSWIRE
07 Nov 2024

https://www.prnewswire.com/news-releases/arthex-biotech-announces-first-patient-dosed-in-phase-i-iia-arthemir-trial-for-myotonic-dystrophy-type-1-dm1-302279972.html

PR NEWSWIRE
18 Oct 2024

https://www.prnewswire.com/news-releases/arthex-biotech-receives-ind-clearance-from-fda-to-initiate-the-phase-i-iia-arthemir-trial-of-atx-01-for-myotonic-dystrophy-type-1-dm1-302073670.html

PR NEWSWIRE
28 Feb 2024

https://www.prnewswire.com/news-releases/arthex-biotech-announces-presentations-at-the-19th-annual-meeting-of-the-oligonucleotide-therapeutics-society-ots-and-tides-europe-2023-301966056.html

PR NEWSWIRE
24 Oct 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty